Yesterday, three of our colleagues took part in the Greenhope Family Day – Sports Against Cancer event, held in San Bernardino, Switzerland. This meaningful event brought together sport, solidarity, and community in support of the Greenhope Foundation and its mission to assist young cancer patients and their families through the power of sport. Helsinn is proud to support the Greenhope Foundation and its inspiring cause! #Helsinn #Greenhope #SportsAgainstCancer
About us
Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology, and dermato-oncology. Founded in 1976, Helsinn has nearly 50 years of experience in the pharmaceutical industry, with an extensive network of long-standing trusted partners enabling a commercial presence in about 150 countries. Helsinn Healthcare SA, headquartered in Lugano (Switzerland), oversees the activities of the three Helsinn Group’s subsidiaries (Helsinn Birex Pharmaceuticals Ltd., Helsinn Therapeutics (U.S.), Inc., Helsinn Pharmaceuticals (Beijing) Co., Ltd.), defining and implementing the Group’s strategy. Our mission is to champion and support patients with cancer and chronic diseases at every stage of their journey, by providing them with the best medications and solutions based on their needs and preferences. Follow our LinkedIn page to stay updated with news from Helsinn Group! If you are interested in joining us, please visit our website (www.helsinn.com): applications should only be submitted via the appropriate country portal, available under “Careers – Join us” website section. * This account shall only be used to share news concerning Helsinn. We would like to emphasize that due to the highly regulated nature of the pharma industry, we cannot engage with you online in any discussions concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional.
- Website
-
http://www.helsinn.com
External link for Helsinn Group
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Lugano/Pazzallo, Ticino
- Type
- Privately Held
- Founded
- 1976
Locations
Employees at Helsinn Group
Updates
-
📢 A mid-year message from our Group CEO As we’ve crossed into the second half of 2025, Dr. Melanie Rolli reflects on Helsinn’s key milestones and achievements so far. 👉 Swipe through the carousel to explore the highlights that are shaping our future. #CEOTalks #Helsinn #PartnerInYourJourney
-
Today is #EarthOvershootDay, the point in the year when our consumption of ecological resources exceeds what the Earth can renew in a year. This serves as a powerful reminder of the urgent need to rethink our lifestyles, consumption habits, and interactions with our planet. At Helsinn, we recognise the crucial connection between human health and planetary health. As a carbon-neutral company for 5 years, we are committed to minimising our environmental footprint through a wide range of measures - including the use of renewable energy, both auto produced via photovoltaic systems in Switzerland and Ireland and purchased from the grid as certified green electricity in Switzerland. We also work to optimise and recycle resources across our sites: in Ireland employees are trained and engaged in proper waste sorting, while in Switzerland food waste is minimised thanks to a smart canteen system where meals are pre-ordered to avoid surplus. Every effort matters! Let's join forces to #MoveTheDate and work towards a sustainable future for all. #Helsinn #Sustainability #CarbonNeutral
-
-
We are delighted to announce the renewal of our commercial agreement with Grünenthal Group to continue supporting patients through their cancer treatment journey by preventing chemotherapy-induced nausea and vomiting (CINV) in Chile. #Helsinn #Partnership #SupportiveCare
-
-
Exciting progress is being made for the AC01 (HM01) molecule. We congratulate our partner AnaCardio on their great result!
AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF 🫀
-
Helsinn Group reposted this
The stage is set for #MASCC25! If you're attending the The Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting, come visit us at booth 12. We're excited to share with you our dedication to supporting cancer patients’ treatment journey. #MASCC25 #SupportiveCare #SuppOnc
-
-
We're excited to keep the momentum going with the third episode of #HelsinnConversations! 🎬 Ready to dive into Helsinn? Join us as Enrico Florio, Alliance Manager, and Monica Pisani, Data & AI Management Officer, reveal their favourite projects and share more fascinating insights! 📺 Tune in now and be sure to leave your comments! #Helsinn #OurPeople
-
Last week, we had the pleasure of hosting a brand meeting at our Lugano headquarters, centred around Mycosis Fungoides-Cutaneous T-Cell Lymphoma (MF-CTCL). Under the inspiring theme "Together We Thrive", this event was a fantastic opportunity to exchange insights and advancements with our commercial partners, Recordati and Rafa Laboratories. Throughout the meeting, we shared best practices, discussed ongoing medical and marketing activities, and laid out future plans. By working together, we can leverage our collective expertise and resources to increase the awareness about MF-CTCL, anticipate the diagnosis, ultimately improving outcomes and patient’s quality of life. Our approach to partnerships is a key strength that drives us to constantly improve our solutions and better meet the patients’ needs. Together, we are making strides in the fight against rare diseases, ensuring that no patient is left behind. #Helsinn #GlobalBrandMeeting #TogetherWeThrive #Partnerships
-
-
Helsinn Group reposted this
Today we want to celebrate our longstanding relationship with the Cutaneous Lymphoma Foundation! Your unwavering dedication has a profound impact on the lives of patients and their families. We share a commitment to improve patient education and awareness about cutaneous lymphoma, provide comprehensive support to people affected by this rare disease and pursue research initiatives to improve treatments. Thank you for your incredible work and commitment. We look forward to making even greater strides in patient care and support. #Helsinn #CutaneousLymphomaFoundation #PatientSupport
-
-
Melissa Clayton, Alessandra Cogliati PharmD, Donna Roche, Silvia Olivari Tilola and Valeriia Zinoveva are attending the International Society for Cutaneous Lymphomas (ISCL) 2025 Annual Scientific & Business Meeting, taking place today in Lugano, Switzerland. This meeting is a fantastic opportunity for Helsinn to connect with leading experts in the field and discuss the latest advancements in cutaneous lymphomas! #ISCL2025 #CutaneousLymphoma #MycosisFungoides
-